Gold Forum Europe April 2024 Cautionary Statements Forward-Looking Statements: This presentation includes "forward-looking statements" within the meaning of U.S. federal securities laws. Forward-looking statements are any statements other than statements of historical fact. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from these statements. Forward-looking statements are often identified by words like "will," "may," "could," "should," "would," ...

Company Overview and Strategy - Natural Grocers operates 169 stores in 21 states west of the Mississippi River as of March 31, 2025[14] - The company's {N}power customer rewards program penetration represented approximately 81% of total sales in Q2 2025[29] - Natural Grocers brand products represented 8.6% of total sales in Q2 2025, up from 8.5% in Q2 2024[32] Market Opportunity and Growth - The U S natural and organic products industry sales grew an estimated 5.7% to $325 billion in 2024[42] - Organic fresh produce sales increased 5.7% in 2024 to $9.5 billion[42] - U S dietary supplement sales grew an estimated 5.2% to $69.3 billion in 2024[42] Financial Performance and Outlook - Daily average comparable store sales grew 8.9% in Q2 2025[60] - Net income increased 64.6% to $13.1 million, and diluted earnings per share increased 60.0% to $0.56 in Q2 2025[60] - The company has $21.2 million in cash and $45.2 million in debt as of March 31, 2025[63] - The company is raising its fiscal 2025 outlook for daily average comparable store sales growth to 6.5% to 7.5% and diluted earnings per share to $1.78 to $1.86[70]

Mining Forum Europe April 2025 Cautionary Statements Forward-Looking Statements: This presentation includes "forward-looking statements" within the meaning of U.S. federal securities laws. Forward-looking statements are any statements other than statements of historical fact. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from these statements. Forward-looking statements are often identified by words like "will," "may," "could," "should," "would ...

CORPORATE OVERVIEW April 2025 MARINE PRODUCTS CORPORATION FORWARD LOOKING STATEMENTS NON-GAAP DISCLOSURE Certain statements and information included in this press release constitute "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements that look forward in time or express management's beliefs, expectations, hopes or strategies. In particular, such statements include, without limitation: our plans to begin ...

Company Overview - Robert Half's 2024 service revenues reached $5.80 billion[6] - The company boasts a 20-year average return on invested capital of 26%[6] - Robert Half has a global presence in 32 countries[5] - The company's full-time internal staff totals 14,700 as of December 31, 2024[6] Revenue Mix & Performance - In Q1 2025, contract talent solutions accounted for 57% of global revenues[20] - Permanent placement talent solutions represented 8% of Q1 2025 global revenues[20] - Protiviti contributed 35% to the company's Q1 2025 global revenues[20] - The United States accounts for 77% of talent solutions revenue mix[17] Financial Strength - The company maintains a strong balance sheet with zero debt[76] - As of March 31, 2025, Robert Half's cash reserves stood at $342 million[76]

Vafseo Launch and Market Opportunity - Vafseo (vadadustat) has launched as a treatment for anemia due to chronic kidney disease (CKD) in adult patients on dialysis[8] - The U S market opportunity for Vafseo in the dialysis patient population is approximately $1 billion[8] - Akebia is pursuing label expansion of Vafseo for the late-stage non-dialysis CKD population, representing a multi-billion-dollar U S market opportunity[8] - Contracts are secured covering nearly 100% of U S dialysis patients for Vafseo[12, 20] Clinical and Patient Considerations - Current standard of care for dialysis patients (ESAs) has remained unchanged for 30 years, with nearly 25% of patients falling below target hemoglobin levels[13] - Approximately 20% of patients on dialysis are ESA hyporesponders, leading to higher hospitalization and mortality rates[13] - Market research indicates that over 2 out of 3 nephrologists identify an unmet need for anemia treatment in CKD, particularly for oral options and ESA-resistant patients[14] VOICE Trial and Label Expansion - The VOICE trial, with over 650 subjects enrolled as of January 10, 2025, is designed to demonstrate non-inferiority for all-cause mortality and superiority for a 10% reduction in all-cause hospitalization[23, 24] - A Phase 3 clinical trial for Vafseo in late-stage CKD patients not on dialysis is planned to begin in mid-2025[8, 46] Non-Dialysis Market - In patients with pre-hemodialysis Hb <9 0 g/dL (n=4855), 73 4% did not receive ESA pre-HD[26] - The U S non-dialysis market opportunity for anemia treatment is approximately $1 billion, driven by predominantly private and unbundled government payment structures[40, 41] HIF-based Pipeline - Akebia is advancing a HIF-based pipeline targeting high unmet needs, including ROP (rare disease) with a ~$1 5B+ U S market opportunity and ~30K patients[50]

Vafseo Launch and Market Opportunity - Vafseo (vadadustat) has launched as a treatment for anemia due to chronic kidney disease (CKD) in adult patients on dialysis[8] - The U S market opportunity for Vafseo in the dialysis patient population is approximately $1 billion[8] - Akebia is pursuing label expansion of Vafseo for the late-stage non-dialysis CKD population, representing a multi-billion-dollar U S market opportunity[8] - Contracts are secured covering nearly 100% of U S dialysis patients for Vafseo[12, 20] Clinical and Patient Considerations - Current standard of care for dialysis patients (ESAs) has remained unchanged for 30 years, with nearly 25% of patients falling below target hemoglobin levels[13] - Approximately 20% of patients on dialysis are ESA hyporesponders, leading to higher hospitalization and mortality rates[13] - Market research indicates that over 2 out of 3 nephrologists identify an unmet need for anemia treatment in CKD, particularly for oral options and ESA-resistant patients[14] Vafseo Advantages and Ongoing Trials - Vafseo is an oral HIF-PH inhibitor with the potential to become standard of care, offering a unique mechanism of action and convenient oral dosing[15] - The VOICE trial, with a target enrollment of ~2,200 patients, is underway to demonstrate Vafseo's non-inferiority for all-cause mortality and superiority for a 10% reduction in all-cause hospitalization[24] Non-Dialysis Market and Future Plans - In patients with pre-hemodialysis Hb <9 0 g/dL (n=4855), 73 4% did not receive ESA pre-HD[26] - A Phase 3 clinical trial is planned to begin in mid-2025 for Vafseo in patients with late-stage CKD anemia not on dialysis, targeting ~1,500 U S subjects[8, 46] Pipeline and Financial Outlook - Akebia expects its existing cash resources and cash from operations to be sufficient to fund its current operating plan for at least two years[8] - Akebia is advancing a HIF-based pipeline targeting high unmet needs, including ROP (~$1 5B+ U S market opportunity), ARDS (~$2B U S market opportunity), and CS associated AKI (~$1 5B+ U S market opportunity)[50]

Financial Performance Highlights - Hellios Pool TCE (Time Charter Equivalent) per Available Day was $49,502[12] - Hellios Pool Spot + COA TCE per Available Day reached $51,481[12] - Fleet TCE per Operating Day amounted to $51,888[12] - Spot TCE per Operating Day was $55,470[12] Operational Efficiency - Fleet Utilization was 91.7%[12] - Spot Fleet Utilization was 90.7%[12] Expense Management - Fleet OpEx (Operating Expense) was $9,407 per Calendar Day[12] - Fleet OpEx (excluding drydock) was $8,556 per Calendar Day[12] Balance Sheet (as of March 31, 2020) - Total Cash and Marketable Securities stood at $102.3 million[11] - Total Debt Obligations amounted to $646.1 million[11] Cash Flow (Three Months Ended March 31, 2020) - Net income was $29,425,391 compared to a net loss of $(15,953,575) for the same period in 2019[13]

Business Overview - Bright Horizons' 2024 revenue reached $2686 million[8], with an adjusted EBITDA of $409 million[8] and an adjusted EBITDA margin of 15.2%[8] - The company operates 1,019 centers globally[8] and serves over 1,450 clients[8], maintaining a 95% employer-sponsored center client retention rate[8] - Bright Horizons manages over $1 billion in tuition[10] and covers over 3 million employees with college advising services[10] Growth and Financial Performance - The company has a 25+ year history of sales growth, excluding the COVID-19 disruption in 2020[8] - Back-Up Care revenue reached $610 million in 2024[10], a significant increase from $296 million in 2019[10] - Educational Advisory revenue increased to $114 million in 2024[10], up from $82 million in 2019[10] Client Base and Market - Bright Horizons serves a diversified blue-chip client base, including over 220 of the Fortune 500[23] - The largest customer accounts for 1% of revenue, and the top 10 customers account for 8% of revenue[23] - The company's customer end markets include Tech (32%), Healthcare & Pharmaceuticals (17%), and Professional Services/Other (12%)[23] Q4 2024 Performance - Total revenue for Q4 2024 was $674 million, a 10% increase compared to $616 million in Q4 2023[61] - Adjusted EBITDA for Q4 2024 was $111 million, a 12% increase compared to $99 million in Q4 2023[61] - Adjusted EPS for Q4 2024 was $0.98, an 18% increase compared to $0.83 in Q4 2023[61]

Company Overview - Astrana Health is a healthcare platform focused on accessible, high-quality, high-value care through a provider-centric, technology-driven approach[7] - The company has a significant scale with 12,000+ providers and 1.1 million members in value-based care arrangements[9] - Astrana Health operates across 16 markets with 20+ payer partners[9] Financial Performance - Astrana Health's FY 2024 Adjusted EBITDA was $170.4 million[10] - The company's FY 2024 revenue was $2.03 billion[10] - The company projects revenue between $2.5 billion and $2.7 billion for FY 2025[31] - The company projects Adjusted EBITDA between $170 million and $190 million for FY 2025[31] Growth and Strategy - Astrana Health's revenue has grown at a Compound Annual Growth Rate (CAGR) of approximately 29%[25] - Adjusted EBITDA has grown at a CAGR of approximately 22%[27] - 38% of Astrana Health's members are in full-risk arrangements[35] - The company's playbook includes growth, risk progression, outcomes and cost management, and operating leverage[35]